Your browser doesn't support javascript.
Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.
Wang, Jingya; Cooper, Jennifer M; Gokhale, Krishna; Acosta-Mena, Dionisio; Dhalla, Samir; Byne, Nathan; Chandan, Joht Singh; Anand, Astha; Okoth, Kelvin; Subramanian, Anuradhaa; Bangash, Mansoor N; Jackson, Thomas; Zemedikun, Dawit; Taverner, Tom; Hanif, Wasim; Ghosh, Sandip; Narendran, Parth; Toulis, Konstantinos A; Tahrani, Abd A; Surenthirakumaran, Rajendra; Adderley, Nicola J; Haroon, Shamil; Khunti, Kamlesh; Sainsbury, Christopher; Thomas, G Neil; Nirantharakumar, Krishnarajah.
  • Wang J; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Cooper JM; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Gokhale K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Acosta-Mena D; Cegedim Health Data, Cegedim Rx, London, UK.
  • Dhalla S; The Health Improvement Network (THIN), London, UK.
  • Byne N; Cegedim Health Data, Cegedim Rx, London, UK.
  • Chandan JS; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Anand A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Okoth K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Subramanian A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Bangash MN; Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.
  • Jackson T; Department of Critical Care, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Zemedikun D; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
  • Taverner T; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Hanif W; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Ghosh S; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Narendran P; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Toulis KA; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Tahrani AA; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Surenthirakumaran R; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Adderley NJ; Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Haroon S; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Khunti K; Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK.
  • Sainsbury C; Department of Community and Family Medicine, Faculty of Medicine, University of Jaffna, Jaffna, Sri Lanka.
  • Thomas GN; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Nirantharakumar K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
J Clin Endocrinol Metab ; 106(5): 1255-1268, 2021 04 23.
Article in English | MEDLINE | ID: covidwho-1073065
ABSTRACT

OBJECTIVE:

Diabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes. RESEARCH DESIGN AND

METHODS:

We performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed.

RESULTS:

There were 29 558 and 10 271 patients in the MF+ and MF- groups, respectively, who met the inclusion criteria. In the propensity score-matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding.

CONCLUSION:

Current prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents / Metformin Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Endocrinol Metab Year: 2021 Document Type: Article Affiliation country: Clinem

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents / Metformin Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Endocrinol Metab Year: 2021 Document Type: Article Affiliation country: Clinem